Considering switching CGRP medications for migraine? Learn what the evidence shows about response rates, timing, and what to track before your next appointment.
Deciding whether to keep going with a current preventive therapy or try something different is one of the most common questions in migraine care. For people using CGRP-targeting treatments, the decision is nuanced: these medications work well for many, but not for everyone, and there is now real-world experience to draw on when thinking about switching CGRP medications for migraine.
This article walks through what the evidence says about treatment response, why some people switch, what to track before making that call, and what questions to bring to your clinician.
CGRP-targeting therapies are a class of preventive treatments, not a single drug. They work either by blocking the CGRP molecule itself or by blocking the receptor it binds to. Within that class there are injectable monoclonal antibodies dosed monthly or quarterly, as well as oral small-molecule options taken daily. The binding targets and molecular structures differ between agents, which matters more than it might seem.
A non-response to one agent does not reliably predict non-response to all agents in the class. This is one of the key takeaways from clinical observations over the past several years. People who saw no meaningful benefit from a first CGRP-targeting therapy have, in a meaningful proportion of cases, responded to a second one. The reverse is also true: side effects that were problematic with one agent have sometimes been absent with another.
That said, switching is not without tradeoffs. It takes time, involves prior authorization processes that can be slow (see CGRP prior authorization and renewal), and the new agent still requires its own adequate trial period before conclusions can be drawn.
The standard recommendation is a minimum of three months at a therapeutic dose before calling a treatment ineffective. This threshold exists because CGRP antibodies accumulate over months and response can build gradually. Some people experience a clear reduction in monthly migraine days within the first month; others see the curve bend more slowly.
The problem with shorter trials is that you risk abandoning something that would have worked. The problem with extending a clearly ineffective trial is that you lose time and sometimes worsen overall burden. Three months is the consensus minimum, but the right call depends on whether there is any signal of benefit, however modest, versus a flat response with no movement at all.
Partial responders present the hardest question. If migraine frequency dropped from 18 days per month to 12, is that a success or a failure? There is no universal answer. Tools like the MIDAS calculator or HIT-6 calculator can help quantify functional impact at baseline and after treatment, giving you and your clinician something concrete to compare.
Clinically, a 50 percent reduction in monthly migraine frequency is often used as the benchmark for meaningful response. But that threshold does not capture everything that matters to someone living with migraine. Severity, duration, how often rescue medications are needed, and functional impairment all factor in.
The MIDAS and HIT-6 scales were designed to capture exactly this kind of broader impact. Running those scores at the start of a treatment trial and again at three months gives you a structured before-and-after comparison that is far more useful in a clinical conversation than "I think it's a little better."
You can also use the migraine reduction calculator to put numbers to your change in frequency and see how it stacks up against typical response thresholds.
If you are approaching the end of a trial period and considering a change, the quality of your tracked data will directly affect the quality of the clinical conversation.
At minimum, track:
A structured migraine log shared with your doctor is worth more than the same information recalled from memory in a 15-minute appointment. Clinicians are making consequential decisions; give them real data.
Not every next step is a switch. Depending on your situation, options a neurologist might consider include:
The decision tree is genuinely complex and depends on whether you have episodic or chronic migraine, what other treatments have been tried, your insurance situation, and your own priorities. This is exactly the kind of conversation that benefits from organized data.
Large-scale randomized trial data on sequential CGRP therapy is limited because most pivotal trials enrolled people who were naive to the class. Real-world registry data and smaller prospective studies have generally found:
None of this means switching will work for everyone, and it does not tell you which agent to try next. That is a clinical judgment your neurologist makes based on your full history.
If you do switch, starting a fresh baseline on day one of the new treatment is valuable. The measuring CGRP progress guide covers what to capture and when, including how to set a clean pre-treatment baseline even if you have been on preventive therapy before.
Use the app to log migraine days and severity consistently throughout the new trial. Patterns that emerge over 8 to 12 weeks are far more informative than a snapshot from one bad week or one unusually good stretch.
Remember: only your clinician can start, stop, or change any preventive treatment. What you can control is the completeness and accuracy of the data you bring to that decision.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
Clinical experience and observational data suggest that some people who do not respond to one CGRP-targeting therapy do respond to another. The mechanisms and binding targets differ between agents, which may explain individual variation. Your neurologist can weigh whether a trial of a different agent makes sense for you.
Understand what to do if CGRP medication doesn't work, why partial or no response happens, and what questions to bring to your neurologist.
CGRP vs Botox for migraine: how each works, who qualifies, and what to track to help your doctor choose the right prevention approach.
Learn how CGRP first line migraine prevention guidelines are shifting, what this means for patients, and what to track to support your treatment decisions.
